3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
6
Lymphoma, Follicular
6
Lymphoma, Large B-Cell, Diffuse
3
Neoplasms by Histologic Type
1
Neoplasms
1
Lymphoproliferative Disorders
1
Lymphoma, B-Cell
1
Lymphoma
1
Lymphatic Diseases
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Interventions
Dexamethasone
2
Bortezomib
2
ponatinib
1
pegaspargase
1
isatuximab
1
ibrutinib
1
ibritumomab tiuxetan
1
cirmtuzumab
1
blinatumomab
1
asparaginase erwinia chrysanthemi recombinant
1
Vorinostat
1
Rituximab
1
Methotrexate
1
Melphalan
1
Lenalidomide
1
Imatinib Mesylate
1
Ifosfamide
1
Etoposide
1
Daunorubicin
1
Cytarabine
1
Carmustine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Immunoproliferative Disorders
×
ibritumomab tiuxetan
×
Clear all
NCT02366663
2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3
Terminated
3 enrolled
8 charts